XERMELO MARKETED BY: Lexicon PharmaceuticalsINDICATION: The FDA has approved Xermelo (telotristat ethyl) 250 mg as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.DOSAGE FORM: Tablets: 250 mgFOR MORE INFORMATION: xermelo.comQTERN MARKETED BY: AstraZenecaINDICATION: AstraZeneca has announced the FDA approval of once-daily Qtern (10 mg dapagliflozin and 5 mg saxagliptin) for the treatment of type 2 diabetes. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes who have inadequate control with dapagliflozin or who are already being treated with dapagliflozin and saxagliptin.DOSAGE FORM: Tablet: 10 mg dapagliflozin/5 mg saxagliptinFOR MORE INFORMATION: astrazeneca.comKISQALI MARKETED BY: NovartisINDICATION: The FDA has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as initial endocrine-based therapy treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.DOSAGE FORM: TABLETS: 200 mgFOR MORE INFORMATION: Novartis.comKEYTRUDAMARKETED BY: MerckINDICATION: The FDA has approved Keytrudaâ€™s indication for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapy.DOSAGE FORM: Injection: 200 mg for adults; up to 200 mg for pediatricsFOR MORE INFORMATION: Keytruda.com
